These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30637967)

  • 1. Injection site reactions with the use of biological agents.
    Thomaidou E; Ramot Y
    Dermatol Ther; 2019 Mar; 32(2):e12817. PubMed ID: 30637967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Injection Site Reactions to Biologic Agents Used in Psoriasis and Psoriatic Arthritis.
    Henderson Berg MH; Carrasco D
    J Drugs Dermatol; 2017 Jul; 16(7):695-698. PubMed ID: 28697222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential diagnosis of late-type reactions to injected local anaesthetics: Inflammation at the injection site is the only indicator of allergic hypersensitivity.
    Trautmann A; Stoevesandt J
    Contact Dermatitis; 2019 Feb; 80(2):118-124. PubMed ID: 30311217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.
    Scavone C; Sessa M; Clementi E; Corrao G; Leone R; Mugelli A; Rossi F; Spina E; Capuano A
    BioDrugs; 2018 Dec; 32(6):607-617. PubMed ID: 30341487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Injection site reactions after subcutaneous oligonucleotide therapy.
    van Meer L; Moerland M; Gallagher J; van Doorn MB; Prens EP; Cohen AF; Rissmann R; Burggraaf J
    Br J Clin Pharmacol; 2016 Aug; 82(2):340-51. PubMed ID: 27061947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis.
    Grace E; Goldblum O; Renda L; Agada N; See K; Leonardi C; Menter A
    Dermatol Ther (Heidelb); 2020 Feb; 10(1):99-106. PubMed ID: 31734937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials.
    Shear NH; Paul C; Blauvelt A; Gooderham M; Leonardi C; Reich K; Ohtsuki M; Pangallo B; Xu W; Ball S; Ridenour T; Torisu-Itakura H; Agada N; Mallbris L
    J Drugs Dermatol; 2018 Feb; 17(2):200-206. PubMed ID: 29462229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are Injection Site Reactions in Monoclonal Antibody Therapies Caused by Polysorbate Excipient Degradants?
    Singh SK; Mahler HC; Hartman C; Stark CA
    J Pharm Sci; 2018 Nov; 107(11):2735-2741. PubMed ID: 30055223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Systematic Review and Meta-Analysis of Injection Site Reactions in Randomized-Controlled Trials of Biologic Injections.
    Kim PJ; Lansang RP; Vender R
    J Cutan Med Surg; 2023; 27(4):358-367. PubMed ID: 37533141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localized inflammatory reactions at sites of subcutaneous methotrexate injections during treatment with ultraviolet B.
    Muthiah S; Charlton F; Farr PM
    Br J Dermatol; 2018 Jul; 179(1):192-194. PubMed ID: 29341063
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparing incidences of infusion site reactions between brand-name and generic vinorelbine in patients with non-small cell lung cancer.
    Ozawa N; Hase T; Hatta T; Sagara A; Ichikawa K; Miyazaki M; Yogo N; Ando M; Hashimoto N; Yamada K; Hasegawa Y
    Br J Clin Pharmacol; 2021 Mar; 87(3):1318-1326. PubMed ID: 32790917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clobetasol pretreatment to reduce and prevent injection site dermatitis from biologic agents.
    Liu D; Wu DJ; Rajpara A; Wang T; Aires DJ
    J Am Acad Dermatol; 2019 Apr; 80(4):e71. PubMed ID: 30222987
    [No Abstract]   [Full Text] [Related]  

  • 13. Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study.
    Megna M; Battista T; Noto M; Picone V; Fabbrocini G; Ruggiero A; Genco L
    Clin Cosmet Investig Dermatol; 2023; 16():553-564. PubMed ID: 36896374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.
    Gerdes S; Thaçi D; Griffiths CEM; Arenberger P; Poetzl J; Wuerth G; Afonso M; Woehling H
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):420-427. PubMed ID: 28960486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systematic Literature Review of Injection Site Pain Perception in Adult Patients Treated with Citrate-Free and Citrate-Containing Biologic Agents.
    Junker S; Ebert O; Bartsch R
    Curr Rheumatol Rev; 2023 Jun; 19(3):303-313. PubMed ID: 36043729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations.
    Juergens C; Trammel J; Shoji Y; Patterson S; Watson W; Webber C; Gruber WC; Scott DA; Schmoele-Thoma B
    Hum Vaccin Immunother; 2018; 14(8):1948-1956. PubMed ID: 29543583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of histopathological findings at the injection site following degarelix administration.
    Maeda T; Kosaka T; Honda A; Okata U; Hayakawa N; Ito Y; Nagata H; Chen KR; Nakamura S; Oya M
    Support Care Cancer; 2015 May; 23(5):1377-81. PubMed ID: 25358643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The design of clinical trials to support the switching and alternation of biosimilars.
    Faccin F; Tebbey P; Alexander E; Wang X; Cui L; Albuquerque T
    Expert Opin Biol Ther; 2016 Dec; 16(12):1445-1453. PubMed ID: 27666115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.
    Griffiths CEM; Thaçi D; Gerdes S; Arenberger P; Pulka G; Kingo K; Weglowska J; ; Hattebuhr N; Poetzl J; Woehling H; Wuerth G; Afonso M
    Br J Dermatol; 2017 Apr; 176(4):928-938. PubMed ID: 27787890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-beta injection site reactions in patients with multiple sclerosis.
    Maurelli M; Bergamaschi R; Antonini A; Fargnoli MC; Puma E; Mallucci G; Totaro R; Girolomoni G
    J Dermatolog Treat; 2018 Dec; 29(8):831-834. PubMed ID: 29671656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.